VERAXA Biotech (NASDAQ: VRXA) has entered into a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC pipeline of T-cell engagers and future antibody-drug conjugates. The partnership aims to integrate artificial intelligence into VERAXA's research and development strategy to enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed due to toxicity.
The collaboration will initially focus on developing AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA's BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity. By leveraging Ardigen's expertise in AI and bioinformatics, VERAXA expects to strengthen its development of precision oncology therapies and improve long-term drug development success rates.
"We are excited to collaborate with Ardigen to harness the power of AI in our drug discovery process," said a spokesperson for VERAXA. "This partnership aligns with our commitment to advancing next-generation antibody-based therapeutics and improving outcomes for patients with cancer."
VERAXA Biotech is focused on building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research. VERAXA's BiTAC platform is designed to address key limitations of current T-cell engagers, such as on-target off-tumor toxicity, by enabling more precise targeting of tumor cells.
The integration of AI into drug development is increasingly recognized as a critical tool for improving the efficiency and success rates of oncology pipelines. By analyzing vast amounts of data from preclinical and clinical studies, AI can help identify the most promising target combinations and predict potential toxicity issues early in the development process.
For more information, the full press release is available at https://ibn.fm/GLFg2. Additional updates and news regarding VERAXA Biotech can be accessed in the company's newsroom at http://ibn.fm/VRXA.
